Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 in MTAP-deleted Advanced Solid Tumors
2025-524285-18-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label trial of MRTX1719 in Nonhematologic neoplasms, melanoma, gastric adenocarcinoma and 6 more (10 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate (OR) and Safety and tolerability of BMS-986504 combinations. Planned start Aug 2026; status: authorised.
02
Drugs
MRTX1719
03
Conditions
Nonhematologic neoplasmsmelanomagastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2025-524285-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524285-18-00.